COMPANY

YourChoice Therapeutics

Location: Berkeley, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Male Contraception YCT-529

Funding and NIH signals

NIH award NIH awarded $994K (SBIR Phase II 1R44HD120117-01A1, new, notice Sep 17, 2026). NIH RePORTER 1R44HD120117-01A1 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 1R44HD120117-01A1
  Organization: YOURCHOICE THERAPEUTICS, INC.; City/State: Berkeley, CA; Project number: 1R44HD120117-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 994056; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Tablet development and relative bioavailability study in men for ongoing clinical development of YCT-529 as an oral non-hormonal male contraceptive; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Sep 11, 2024 Trial start Phase 1/Phase 2: Open Label, Dose Escalation, Repeat Dose Study Evaluating YCT-529 in Healthy Males source ↗
Dec 20, 2023 Trial start Phase 1: First in Human Study Evaluating Single Ascending Oral Doses of YCT-529 in Healthy Males source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06542237	Open Label, Dose Escalation, Repeat Dose Study Evaluating YCT-529 in Healthy Males	Phase 1/Phase 2	Recruiting	Sep 11, 2024	Jul 31, 2026 (estimated)
NCT06094283	First in Human Study Evaluating Single Ascending Oral Doses of YCT-529 in Healthy Males	Phase 1	Completed	Dec 20, 2023	Jun 18, 2024 (actual)